商業快報

Psychedelic nasal spray shows promise against depression
致幻鼻噴霧劑顯示出對抗抑鬱症的潛力

Mebufotenin benzoate also required a much shorter period of clinical supervision in trial
Mebufotenin benzoate的臨牀試驗讓生物技術公司看到了希望,即此類藥物有望成爲治療精神疾病的可行選擇。

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against treatment-resistant depression, giving biotechs hope that this type of drug will become a viable option for healthcare systems to use for mental health conditions. 

一種需要更短臨牀監督期的致幻劑鼻噴霧劑已顯示出對抗難治性抑鬱症的潛力,這讓生物技術公司看到了希望,即此類藥物有望成爲醫療系統用於治療精神疾病的可行選擇。

您已閱讀8%(348字),剩餘92%(4222字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×